LOGO
LOGO

Economy And The Numbers

NEXGEL Eyes Over 100% Revenue Growth In 2024 - Will The Stock Get A Facelift?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

NEXGEL Inc. (NXGL), a provider of medical and over-the-counter products, including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, expects revenue growth of over 100% in 2024 and is optimistic about its outlook for 2025.

The company has partnerships with STADA Arzneimittel AG, a European leader in consumer health; Cintas Corp, a provider of corporate identity uniforms, first aid and safety products, and services; and AbbVie Inc. (ABBV), among others.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Economic News

What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.

Global Economics Weekly Update - Sep 07 – Sep 11, 2026

September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.

RELATED NEWS